In the News
In focus: Amid heightened industry rules on sustainability, how are CROs faring?
Michael Cohen takes a look at the progress CROs are making in their sustainability efforts.
AI and real-world data integration: Transforming clinical trials and drug development – panel at DIA Global
Our experts delve into the integration of real-world data and advanced technologies to accelerate drug development.
Breaking barriers: Strategic use of FSP models to expand trials into non-footprint countries
Lisa Beckel discusses how leveraging functional service provider models can enhance global clinical trial reach and inclusion.
From Hematologic to Autoimmune Disease – The CAR-T Therapy Second Revolution
CAR-T therapy has entered a new era with its potential application in autoimmune, metabolic and other chronic conditions. Davide Garrisi and Kim Watanabe explore how CAR-T therapy is poised to make a significant impact on patients' lives.
Five critical elements for maximizing functional service partnerships
As organizations look more to functional service partnership models to outsource specific functions of clinical trials, the authors discuss five keys to successfully implementing those relationships.
Beat the clock: How an FSP model can optimize a follow-the-sun approach in clinical development functions
Our experts discuss how a follow-the-sun model delivered in a flexible functional service provider outsourcing model is being used to respond to more challenging timelines.
How much does a clinical research associate impact a company’s carbon footprint? More than you might think!
Michael Cohen discusses the need to better understand our respective carbon footprints and develop solutions to reduce the environmental impact of clinical trials.
What’s APAC’s recipe of success in clinical trials market?
Ding Ming talks about the ongoing efforts foster an environment that is more conducive to clinical trials.
Real-world evidence key to navigating new policy changes
Evidera’s Ariel Berger and Almudena Olid Gonzalez discuss the expanding role of real-world evidence in drug development.